UNASSIGNED: Recent studies have shown that the lymphocyte to monocyte ratio (LMR) is a useful prognostic factor in various @entity5 . The purpose of the current study was to investigate the association between pretreatment LMR, disease-free survival (DFS), and @entity1349 ( @entity1349 ) in @entity1 with early-stage (I to III) @entity0 ( @entity0 ). Pretreatment LMR with corresponding clinical features from 230 @entity0 @entity1 was noted. A receiver operating characteristic (ROC) curve for survival prediction was plotted to verify the optimal cutoff values for LMR, lymphocyte, and monocyte counts. The difference between variables was calculated using chi-square tests. The Kaplan-Meier method and univariate and multivariate Cox regression models were applied to assess @entity1349 and DFS. Based on the ROC analysis, the optimal cutoff point for LMR was 4.7. Associations between high LMR (>= 4.7) and significantly small @entity5 size (P   =   0.005) and TNM stage (P   =   0.013) were found, although there was no significant association for other clinical pathological factors. In the multivariate analysis, LMR was a significant predictive factor for both @entity1349 (hazard ratio [HR]   =   0.42; 95  % confidence interval [CI], 0.19-0.95; P   <   0.001) and DFS (HR   =   0.40; 95  % CI, 0.20-0.79; P   <   0.001). In addition, the predictive values of the @entity1349 and DFS were also observed for absolute counts of lymphocytes (P   <   0.001) and monocytes (P   <   0.001). Our study suggests that pretreatment LMR may be a predictive factor for long-term survival in @entity1 with early-stage @entity0 .

Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in XXXX with early-stage @entity0 .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['triple-negative breast cancer', 'TNBC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
